Vaxart
Vaccine technology for the treatment of infectious diseases.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (78 %) | (88 %) | 6796 % | 289 % | (25 %) | (58 %) | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (7482 %) | (99139 %) | (978 %) | (191 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (7900 %) | (100708 %) | (1118 %) | (233 %) | (329 %) | (1131 %) | (1188 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 5465 % | 75751 % | 923 % | 259 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Vaxart is a biotechnology company specializing in the development of oral recombinant vaccines. Operating in the rapidly growing $30 billion global vaccines market, Vaxart aims to unlock the full potential of oral vaccines, which are easier to administer and distribute compared to traditional injectable vaccines. The company's platform supports the rapid development, manufacture, and distribution of these vaccines, targeting diseases such as norovirus gastroenteritis and COVID-19. Vaxart primarily serves healthcare providers, governments, and organizations involved in public health. The business model focuses on research and development, clinical trials, and partnerships with larger pharmaceutical companies for commercialization. Revenue is generated through funding, grants, and potential licensing deals.
Keywords: oral vaccines, biotechnology, recombinant vaccines, healthcare, public health, norovirus, COVID-19, clinical trials, R&D, pharmaceutical partnerships.
Tech stack
Investments by Vaxart
Edit